| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10011765 | HBV | ENSG00000092621.13 | protein_coding | PHGDH | No | No | 26227 | O43175 |
| TVIS10011766 | HBV | ENSG00000092621.13 | protein_coding | PHGDH | No | No | 26227 | O43175 |
| TVIS20018372 | HPV | ENSG00000092621.13 | protein_coding | PHGDH | No | No | 26227 | O43175 |
| TVIS44018526 | HTLV-1 | ENSG00000092621.13 | protein_coding | PHGDH | No | No | 26227 | O43175 |
| TVIS44024366 | HTLV-1 | ENSG00000092621.13 | protein_coding | PHGDH | No | No | 26227 | O43175 |
| TVIS44004532 | HTLV-1 | ENSG00000092621.13 | protein_coding | PHGDH | No | No | 26227 | O43175 |
| TVIS44048562 | HTLV-1 | ENSG00000092621.13 | protein_coding | PHGDH | No | No | 26227 | O43175 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PHGDH |
|---|---|
| DrugBank ID | DB00157 |
| Drug Name | NADH |
| Target ID | BE0000161 |
| UniProt ID | O43175 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 2692566; 945314; 12183470 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Grant GA: A new family of 2-hydroxyacid dehydrogenases. Biochem Biophys Res Commun. 1989 Dec 29;165(3):1371-4.@@Goldsmith LA, O'Barr T: Serine biosynthesis in human hair follicles by the phosphorylated pathway: follicular 3-phosphoglycerate dehydrogenase. J Invest Dermatol. 1976 Jun;66(6):360-6.@@Grant GA, Hu Z, Xu XL: Cofactor binding to Escherichia coli D-3-phosphoglycerate dehydrogenase induces multiple conformations which alter effector binding. J Biol Chem. 2002 Oct 18;277(42):39548-53. Epub 2002 Aug 14. |
| Groups | Approved; Nutraceutical |
| Direct Classification | (5'->5')-dinucleotides |
| SMILES | NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O |
| Pathways | Ethylmalonic Encephalopathy; 3-Methylglutaconic Aciduria Type III; Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD Deficiency); Caffeine Metabolism; Fructose and Mannose Degradation; Isovaleric Aciduria; Lysine Degradation; Methylmalonic Aciduria Due to Cobalamin-Related Disorders; Glycerol Phosphate Shuttle; Zellweger Syndrome; Propionic Acidemia; Glycolysis; Xanthine Dehydrogenase Deficiency (Xanthinuria); S-Adenosylhomocysteine (SAH) Hydrolase Deficiency; Tryptophan Metabolism; Glutaric Aciduria Type I; 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I; Glycine N-Methyltransferase Deficiency; Dimethylglycine Dehydrogenase Deficiency; Androgen and Estrogen Metabolism; Nucleotide Sugars Metabolism; 3-Methylglutaconic Aciduria Type IV; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Malate-Aspartate Shuttle; Folate Metabolism; Valine, Leucine, and Isoleucine Degradation; Maple Syrup Urine Disease; Glycerol Kinase Deficiency; Adenylosuccinate Lyase Deficiency; Cysteine Metabolism |
| PharmGKB | PA164755085 |
| ChEMBL | CHEMBL1234616 |
